For instance, in a small pilot study of 55 participants from a randomized controlled trial designed to determine the efficacy of long-term pioglitazone treatment in patients with NASH (NCT00994682), Kawaguchi-Suzuki et al. reported that ADORA1 (Adenosine A1 Receptor) rs903361 was associated with resolution of NASH and improvement in the ballooning score in patients receiving pioglitazone [96]. Here, ADORA1 is linked to metabolic dysfunction-associated steatohepatitis.